Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2023; 14(8): 285-296
Published online Aug 24, 2023. doi: 10.5306/wjco.v14.i8.285
Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail
Ahmed Elhariri, Ahmed Alhaj, Daniel Ahn, Mohamad Bassam Sonbol, Tanios Bekaii-Saab, Christina Wu, Michael Scott Rutenberg, John Stauffer, Jason Starr, Umair Majeed, Jeremy Jones, Mitesh Borad, Hani Babiker
Ahmed Elhariri, Ahmed Alhaj, Jason Starr, Umair Majeed, Jeremy Jones, Hani Babiker, Division of Hematology-Oncology, Department of Medicine, Mayo Clinic Florida, Mayo Clinic Cancer Center, Jacksonville, FL 32224, United States
Daniel Ahn, Mohamad Bassam Sonbol, Tanios Bekaii-Saab, Christina Wu, Mitesh Borad, Division of Hematology-Oncology, Department of Medicine, Mayo Clinic Arizona, Mayo Clinic Cancer Center, Phoenix, AZ 85054, United States
Michael Scott Rutenberg, Department of Radiation-Oncology, Mayo Clinic Florida, Mayo Clinic Cancer Center, Jacksonville, FL 32224, United States
John Stauffer, Department of Surgical Oncology, Hepatopancreatobiliary Surgery, Mayo Clinic Florida, Jacksonville, FL 32224, United States
Author contributions: Elhariri A and Babiker H designed and wrote the manuscript; Alhaj A, Ahn D, Sonbol MB, Bekaii-Saab T, Wu C, Rutenberg MS, Stauffer J, Starr J, Majeed U, Jones J and Borad M critically reviewed and edited the manuscript; All authors approved the final version of the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ahmed Elhariri, MD, Research Fellow, Division of Hematology-Oncology, Department of Medicine, Mayo Clinic Florida, Mayo Clinic Cancer Center, 4500 San Pablo Rd, Jacksonville, FL 32224, United States. Ahmed.Elhariri@bcm.edu
Received: April 12, 2023
Peer-review started: April 12, 2023
First decision: June 21, 2023
Revised: July 5, 2023
Accepted: July 27, 2023
Article in press: July 27, 2023
Published online: August 24, 2023
Processing time: 131 Days and 5.6 Hours
Core Tip

Core Tip: Kirsten rat sarcoma virus (KRAS) mutation is the hallmark of pancreatic cancer (PC) and an important therapeutic target. Approaches to target this oncogene has been challenging. We herein discuss the role of KRAS in development of PC, efforts made to target this pathway, and ongoing clinical trials.